Explore the innovative power behind the list: medical device is going to "new"

Reading Client · Shenzhen News Network, September 6, 2022 (Reporter He Yanjing) At the recent start of the national high -performance medical device Innovation Ecological Summit and major project launching activities, "2022 China High -Performance Medical Device Enterprise Enterprise Xinrui 100" It is officially announced. The high -performance medical device "new star" on the top 100 list has attracted attention from all walks of life.

"2022 China's high -performance medical device enterprise Xinrui Top 100" (hereinafter referred to as the "list") was led by the National High -Performance Medical Device Innovation Center (hereinafter referred to as the "Guochuang Center"). Power, promote the rapid growth of emerging medical device companies. Throughout the list, the list of companies on the list is full of "gold content", behind the "innovative password" of the booming medical device industry.

A number of innovation achievements lead

The new top 100 companies show the vitality of innovation

Innovation is the first driving force to lead the high -quality development of the medical device industry. "The list evaluation system was established with innovation as the core." Liu Xin, deputy director and general manager of the National Innovation Center, introduced that the list was evaluated based on the innovation ability model. The first -level indicators include innovation level, innovation patent, innovation registration, corporate valuation, and corporate growth. The secondary indicators include corporate scale, R & D team, technical strength, market expectations, real performance and capital heat. From the perspective of the selected list of companies, there are many companies in vitro diagnosis, planting equipment and rehabilitation equipment, with 21, 17, and 14 respectively. From the perspective of regional distribution, Shenzhen enterprises have performed well, and more than 30 companies have entered the list, followed by Beijing and Shanghai. Gu Dongfeng, an academician of the Chinese Academy of Sciences, preventing heart disease and epidemiologists, said that the health China cannot be separated from the improvement of medical device products and quality. The list covers all areas of medical devices. Enterprise. Jiang Hai, the business director of Tongchuang Weiye Investment Department, also pointed out that there are many segments of the list of companies and wide regional distribution. The key is that it has a very high technical content.

A number of innovative achievements in the top 100 companies led. Established in 2015, Silicon Bionic Bionic Breaks from foreign technology monopoly in many subdivisions such as continuous blood glucose monitoring (CGM), AI eye screening, artificial retina, capsule gastroscopy robot. AVIC Creation from Xi'an has a complete technical reserve and hundreds of patent layouts. The rehabilitation robots developed and produced have replaced foreign imports. Shenzhen Beishuang Life Technology Co., Ltd. has exceeded a number of "card neck" technology. It has the first approved domestic blood flow reserve score (FFR) measurement system and my country's first self -innovated 60MHz high -speed blood vessel ultrasound (IVUS) product Wait. Shenzhen Frame Guandexin Technology Co., Ltd. has been established in just 7 years. It has cumulatively apply for nearly 600 domestic and foreign invention patents and authorized 200 items. It covers a large number of core technologies such as semiconductor devices, integrated circuits, and manufacturing processes. The "Fourteenth Five -Year Plan" key special research and development.

Innovation is the development password of industry leaders. As a leading company in the medical device industry, Mai Rui Medical adheres to independent research and development and high -quality development, and has risen to become China's largest and leading supplier of medical devices and solutions in the world. Invention patent. From the perspective of Lianying Medical, talent -oriented and mastering core technologies is the key to achieving innovation leadership in enterprises. Not only must we jointly innovate in cooperation in government, industry, research and medical and medical, but also design, services, and market innovation. As of now, Lianying Medical has launched more than 80 products to the market to master completely independent intellectual property rights, which has launched Total-Body PET-CT The overall performance indicators have reached the international first -class level. As a minimally invasive interventional medical device supplier of the world's leading cardiovascular disease, Xianjian Technology has achieved technological breakthroughs from scratch in multiple segments. The blocker occupies the second market share in the world, and the market share of arterial membrane bracket products ranks first in domestic. Cai Qiaowu, vice chairman of the Shenzhen Medical Device Industry Association, said that the scale of my country's medical device industry has risen from less than 1%of the world to a quarter of the world from the beginning of reform and opening up. , Reform, many first -class scientific research institutions provide basic research support.

Innovative capital blessing

Capital is optimistic about medical device investment prospects

Capital attention in the medical device industry has increased year by year. The Chinese medical device market has huge potential, and the organic integration of the medical device industry and capital injects inexhaustible motivation to explore the road of self -innovation and sustainable development of the medical device industry. Data show that in 2021, the number of domestic medical equipment listed companies reached 143, a year -on -year increase of 37; the new IPO raised funds reached 59.6 billion yuan, an increase of 107%year -on -year.

"Capital Hot" is a key indicator of the list selection. A group of enterprises with high technology and good growth are easier to get capital attention and get diversified and differentiated financing services. Jiang Hai, the business director of Tongchuang Weiye Investment Department, believes that the list is obviously more inclined to cutting -edge hard technology companies with medical equipment innovation. This time, the list is an recognition of corporate innovation capabilities and achievements. Financial capital plays a very important role in promoting the innovation and development of small and medium -sized enterprises and entrepreneurial teams in the field of medical devices. Yi Hongxiang, a partner of Shenzhen Venture Capital Health Industry Fund, believes that the company can be said to be an innovative representative in the medical device industry. The listing is expanded for them to expand the popularity of the company and the relevant market visibility. Reference value. Dr. Ge Cheng, Vice President of Sharing Investment and Dr. Shenzhen Overseas Senior Talent, said that medical devices are one of the areas of focusing on investment in investment. The Co., Ltd. entered the list with innovative development in the fields of regeneration medicine, rehabilitation equipment, and in vitro diagnosis. Early venture capital institutions (VCs) must have strong scientific and technological forward -looking and vision of crossing the economic cycle, and have strong policy interpretation and trend judgment ability. According to incomplete statistics, Lianying Medical has been listed on the Science and Technology Board, with a market value of more than 100 billion yuan; AVIC created a financing of tens of millions of yuan in A+rounds in May this year; Hundreds of millions of yuan C financing was completed; Silicon -based bionic also completed more than 500 million yuan C ++ round of financing in early 2022; Beibei Life Technology has conducted multiple rounds of financing in the past five years, with total capital investment of about 1 billion yuan. Innovation is the focus of capital attention. How can companies attract "financial live water"? Yi Hongxiang, a partner of Shenzhen Venture Capital Health Industry Fund, believes that the medical device enterprises should be inspected from the five dimensions of teams, markets, product technology, sales, and compliance operations. Enterprises should focus on the innovation and sales model of product technology. Raise. Dr. Ge Cheng, vice president of investment investment and high -level talents in Shenzhen, said that when seeking financing, the company should consider clearly whether the core technology is introduced or the original research. Meet many aspects such as unsatisfactory clinical needs. Jiang Hai, a business director of Tongchuang Weiye Investment Department, said that enterprises should pay attention to product innovation, combine the characteristics of the track, market characteristics, and corporate capabilities to maintain rhythm.

Create a new type of innovation ecosystem

Help the high -quality development of the high -end medical device industry

Shenzhen has the strength of the high -quality development of the medical device industry. At the level of innovation, more than 30 Shenzhen medical device companies such as Beibei Life Technology, Frame Guanxin, and Silicon -based Bionic occupy the list. At the industrial level, the data shows that as of the end of 2021, Shenzhen had 1,394 medical device production enterprises with 95 companies with an output value of over 100 million yuan. develop. At the policy level, Shenzhen's "20+8" industrial policy lists the high -end medical device industry cluster as one of the key areas of the 20 major strategic emerging industries. Not only that, Shenzhen also proposed to build Shenzhen into a world -renowned high -end medical device research and development center and domestic leading and international first -class high -end medical device industry to gather development goals. In April 2020, with the approval of the Ministry of Industry and Information Technology, the National Innovation Center, which was formally established as a major national technology and industrial innovation platform, officially established and landed in Longhua District of Shenzhen, shoulders the strategic task of building a new type of innovation ecosystem in the medical device industry.

Guochuang Center builds a new type of innovation ecosystem in the medical device industry. For more than two years since its establishment, the Guochuang Center has taken the "innovation leadership, efficient ecology, and service industry" as its thinking. Under the "innovation and operation" double -wheel drive development strategy, it has solidly promoted the integration and expansion of the industrial chain, and actively actively developed the deep research and development chain. The industrial chain, horizontally through the clinical chain, application chain, and capital chain, initially formed an innovative ecosystem for the development of factor convergence, vertical integration, and accurate adaptation of the development of the medical device industry, and gradually play the role of industrial hubs and driving role of national innovation platforms. As the leading unit of the Guochuang Center, the Shenzhen Advanced Academy provided a core engine for the Guochuang Center, injecting cutting -edge technologies into its radiation industry, and took the lead in exploring the "Butterfly Model" of "0-1-10 ∞ ∞". The academician of the Chinese Academy of Engineering said that breaking through the core key technologies, the National Innovation Center assumed the difficult and glorious tasks and mission, to meet the difficulties, and to stand in the position of the country. The domestic gaps and core shortcomings in medical devices play a pivotal effect and support. Gu Dongfeng, an academician of the Chinese Academy of Sciences and the prevention and epidemiologist of the Chinese Academy of Sciences, said that the advantage of domestic medical devices is that no import tax is required, and the output is guaranteed. It is expected that these list companies will be under the innovation system led by Guochuang Center. Promote the high -quality development of the domestic medical device industry. Xu Zongben, an academician of the Chinese Academy of Sciences and a professor at Xi'an Jiaotong University, believes that the Guochuang Center has created a mode of collaborative integration such as medical research, technology development, clinical verification, and marketing. This model is very important and solves the old problem of difficulty in scientific research and technology. Geng Qingshan, Dean of Shenzhen People's Hospital, introduced that the cooperation project of Guochuang Center and the hospital includes the localization of ECMO (vitamin lung) and PET magnetic resonance. The National Innovation Center is a well -combined platform for medical workers. It connects the scientific and technological innovation chain, medical service chain and the enterprise industrial chain. In addition to the participation of "national team", academicians of the two hospitals, and medical scientists, to make more more The effect of domesticization projects is very good. Liu Xin, deputy director and general manager of Guochuang Center, said that in the future, the Guochuang Center will continue to rely on the good environment of "manufacturing in Shenzhen" to continuously improve the industrial chain, innovation chain and strong market response capabilities to attract high -end medical device industry gatherings. Build Shenzhen into a new engine in the medical device industry in the Greater Bay Area.

- END -